Summary: Duloxetine is a balanced selective serotonin and norepinephrine-reuptake inhibitor available in the United States for the treatment of major depressive disorder (MDD) and diabetic ...

Tatton MP Esther McVey has called on the government to provide better guidance to people who are coming off anti-depressants ...

017). Topline results were announced from a phase 3 trial evaluating AXS-12 (reboxetine) in patients with narcolepsy. AXS-12 is an investigational highly selective potent norepinephrine reuptake ...

Once a controversial European depression treatment that never made it to the U.S. | The treatment, which was once a Pfizer ...

The Missouri hospital system designed its own 13-gene PGx panel, which it runs at its molecular genetics lab and calls the ...

CBT is a structured, goal-oriented psychotherapy that focuses on the relationship between a person's thoughts, feelings, and ...

Singer Neha Bhasin shares her battle with PMDD a severe condition beyond PMS Learn about symptoms treatments and the ...

Axsome Therapeutics has announced that its investigational narcolepsy therapy has met the primary endpoint in a Phase III ...

AXS-12 statistically significantly reduced the frequency of cataplexy attacks compared to placebo (p=0.017, primary endpoint) ...

At the start of the year Julie Hiener developed a dramatic stutter. She struggles to get the words out as she tells me: 'I ...

A collection of common and new medications is showing good results against the constellation of symptoms that individualize ...

The company noted that AXS-12 (reboxetine), a highly selective and potent norepinephrine reuptake inhibitor and cortical ...